OptimizeRx Corporation (OPRX)
| Market Cap | 119.52M |
| Revenue (ttm) | 109.43M |
| Net Income (ttm) | 5.13M |
| Shares Out | 18.76M |
| EPS (ttm) | 0.27 |
| PE Ratio | 23.59 |
| Forward PE | 6.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 323,349 |
| Open | 6.40 |
| Previous Close | 6.41 |
| Day's Range | 6.23 - 6.45 |
| 52-Week Range | 5.54 - 22.25 |
| Beta | 1.28 |
| Analysts | Strong Buy |
| Price Target | 16.67 (+161.7%) |
| Earnings Date | May 12, 2026 |
About OPRX
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers’ target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for OPRX stock is "Strong Buy." The 12-month stock price target is $16.67, which is an increase of 161.70% from the latest price.
News
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET
WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthca...
OptimizeRx Appoints Mary Varghese Presti to Board of Directors
Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency Microsoft Health & Life Sciences COO brings ...
OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty
OptimizeRx Corp (NASDAQ: OPRX) shares are tumbling on Friday as the company faces increased market volatility and uncertainty surrounding Most Favored Nation (MFN) pricing.
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Earnings Call Transcript: Q4 2025
Q4 and FY2025 results exceeded expectations with strong revenue, margin expansion, and cash flow. 2026 guidance is more conservative due to market softness, but profitability focus and growth in mid-tier clients remain strong. Share repurchase and debt reduction continue.
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage...
OptimizeRx Continues Expansion of the Company's Point-Of-Care Network
WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx Earnings Call Transcript: Q3 2025
Operational and financial momentum remains strong, with improved revenue visibility and margin expansion driven by subscription-based models and favorable product mix. Guidance is conservative, with stable operating expenses and no contribution from new partnerships like Lamar included.
OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance
- Q3 revenue of $26.1 million, increased 22% year-over-year- Q3 gross profit increased 30% year-over-year to $17.5 million- Increases full year 2025 guidance to a revenue range between $105 mill...
OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference
WALTHAM, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising
Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood ® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth
WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx Earnings Call Transcript: Q2 2025
Q2 2025 saw 55% revenue growth and a return to profitability, with gross margin and cash flow both improving. Guidance for 2025 was raised, and strong contracted revenue growth provides visibility, while accelerated debt repayment and a robust digital offering position the company well.
OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance
WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors
WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions
CANNES, France--(BUSINESS WIRE)-- #TV--Simulmedia announced a strategic partnership with OptimizeRx Corp. to enable the self-serve availability of Micro-Neighborhood® Targeting (MNT).
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage...
OptimizeRx Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 11% year-over-year to $21.9 million, with adjusted EBITDA at $1.5 million and over 80% of full-year revenue already contracted. Guidance was raised to $101–$106 million in revenue and $13–$15 million in adjusted EBITDA, supported by strong pipeline and early subscription model momentum.
OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance
WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage...
OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report
WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage...
OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET
WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...